Jose Raygada, MD
Infectious Disease · Mt Pleasant, MINPI 1063623981
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 72.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $13,137 and has fallen 84.1% since, to $2,094 in 2025. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $103.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$13K
- Mimedx Group, Inc.$1K
- AbbVie$462
- Merck$341
- Smith+Nephew$314
- Melinta Therapeutics, LLC$305
- plus $2K from 18 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$10,35059%
- Travel & lodging$2,26413%
- Food & beverage$4,46125%
- Education$1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 27 | $12,770 |
| Mimedx Group, Inc. | 6 | $1,486 |
| AbbVie(2 entities) | 17 | $462 |
| Merck | 19 | $341 |
| Smith+Nephew | 14 | $314 |
| Melinta Therapeutics, LLC | 14 | $305 |
| Gilead | 14 | $284 |
| Paratek Pharmaceuticals, Inc. | 15 | $267 |
| Kerecis Limited | 6 | $255 |
| Aimmune Therapeutics, Inc. | 3 | $212 |
| Viiv Healthcare Company | 10 | $185 |
| Philips North America LLC | 7 | $154 |
| AstraZeneca | 1 | $115 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $100 |
| La Jolla Pharmaceutical Company | 5 | $85 |
| Shionogi Inc | 1 | $74 |
| Mayne Pharma Commercial LLC | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $17 |
| Medtronic | 1 | $16 |
| Aroa Biosurgery Incorporated | 1 | $15 |
| Organogenesis Inc. | 1 | $15 |
| KCI USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$6,965
- Kerecis Omega3 Marigen$737
- Kerecis Omega3 SurgiClose$184
- ZENPEP$120
- BREZTRI AEROSPHERE$115
How this compares
$17,564 in reported general payments places this provider in the 90th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $179,631 |
| Daptomycin | 124 | $74,376 |
| AvycazCeftazidime/Avibactam | 39 | $58,055 |
| JulucaDolutegravir/Rilpivirine | 11 | $39,831 |
| ErtapenemErtapenem Sodium | 81 | $39,607 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $34,401 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 11 | $10,176 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 55 | $8,617 |
| Meropenem | 37 | $8,261 |
| Methenamine Hippurate | 89 | $5,696 |
| Cefepime Hcl | 32 | $4,168 |
| Fosfomycin Tromethamine | 21 | $3,735 |
| Linezolid | 31 | $2,996 |
| Vancomycin Hcl | 15 | $2,170 |
| Cefazolin Sodium | 34 | $1,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $284 | $179,63146 claims |
| AbbVieAvycaz | $462 | $58,05539 claims |
| Viiv Healthcare CompanyJuluca | $185 | $39,83111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 infectious disease providers in Michigan.
Other infectious disease in Mt Pleasant
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Christopher CarpenterRoyal Oak$27K
- Marcus ZervosDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.